Compliant paid campaigns
Search and social built to survive the ad policies around weight and prescription medication, which restrict more accounts in this category than almost any other.
Medical weight loss
Marketing built for medical weight loss.
GLP-1 demand is the loudest it has ever been, and so is the competition. We build the brand, the campaigns, and the follow-up system that turn that demand into enrolled patients instead of price shoppers.
Medical weight loss is not a discount category, but most marketing treats it like one. Ads compete on the lowest monthly price, the inquiry lands in an inbox nobody watches, and by the time someone follows up the patient has already started somewhere else.
The problem is rarely traffic. It is the gap between an inquiry and a started plan. Speed-to-lead under sixty seconds, a consult that has already answered the obvious objections, and a follow-up sequence that keeps working after the first no are what separate a full program from a busy phone.
We run the whole path as one system: positioning that attracts patients who are ready to commit, compliant campaigns across search and social, a CRM that catches every inquiry from every channel, and reporting that ties spend to started plans rather than clicks.
Ad spend stays separate and goes directly to the platforms. Engagements typically run $1,000 to $5,000 a month depending on service lines and locations.
What we run
The systems behind a full program roster.
Not a channel. The whole path from the first inquiry to the sixth month on plan.
Speed-to-lead under a minute
Every inquiry from every channel answered before the patient has finished comparing your monthly price to the three telehealth brands advertising alongside you.
Consult conversion
Pre-consult sequences that answer cost, side effects, and what happens after the first month, so the consult is about starting rather than deciding.
Intake that survives labs
The gap between signing up and the first dose is where enrolled patients quietly disappear. We keep them engaged through the draw, the results, and the first visit.
Adherence and refills
Reminders and check-ins timed to the refill calendar and to the points where patients typically stall, because a plan abandoned at month two never pays back.
Reporting to started plans
Spend tied to programs started and still running at month six, not to clicks or to a cost per lead that says nothing about who actually enrolled.
Where to start
Weight loss programs start on Growth.
Most weight loss clinics run more than one program, and injectable and non-injectable patients are different conversations that need separate campaigns. Inquiries also arrive at all hours against national competitors who answer instantly. Growth covers both, with up to three campaigns at once and AI handling the first response.
Growth
$899/mo
Take an aggressive position with AI conversion and multiple offers in market.
- AI integrated into landing pages for heightened conversions
- AI across your social & web channels
- Free custom website if you need one
+ 1 more on the Growth plan
See what's included
Questions owners ask
The short answers.
How do we compete with national GLP-1 subscription brands on price?
Not on price. What a national subscription cannot offer is a clinician who knows the patient, labs and follow-up in person, and dose adjustment by someone who answers when side effects appear. That matters most to patients who already tried a cheap subscription, got a standard protocol, and stopped. That group grows every year and is a far better prospect than a first-time price shopper.
What can we say about GLP-1 medications in an ad?
Less than most clinics assume. Naming a branded medication, promising a specific amount of weight loss, or using before and after imagery as the primary creative will get an account restricted, and compounded formulations carry their own advertising and regulatory exposure. We keep campaigns to the program and the consultation, and put the clinical detail on your own site.
Our sign-ups do not make it to their first dose. What is happening?
Usually the lab and authorisation gap. A patient enrols while motivated, then has to book a draw, wait for results, and get through a consult, and that stretch is normally silent. Motivation does not survive silence. Keeping the patient informed across those weeks recovers a large share of the people clinics write off as unserious.
Patients quit around month two or three. Can marketing help with that?
It is mostly a systems problem rather than a clinical one. Patients stall when side effects appear and nobody is easy to reach, when a refill runs out during a busy week, or when the scale stops moving and no one has set the expectation that it would. Sequences timed to those points hold a materially higher share of the roster on plan.
Should injectable and non-injectable programs run in one campaign?
No. They attract different patients with different objections and different price sensitivity, and platform restrictions differ between them. Running them together produces a blended cost per lead that hides which program is working and creative that speaks properly to neither.
How long before the acquisition spend pays for itself?
Rarely in the first month, which is where most clinics judge it and get the answer wrong. A weight loss patient becomes profitable somewhere in the middle of the program and valuable if they complete it, so the number worth watching is patients still on plan at month six against what it cost to enrol them.
One partner, not five